Skip to content
ATLAS PREP HQ
Longevity

Ovagen

Glu-Asp-Leu (EDL) ultrashort peptide bioregulator

Peptide bioregulator research related to gastrointestinal and hepatic tissue function.

Preclinical Evidence

Route

Subcutaneous in the community educational protocol.

Common format

20 mg vial

Research focus

GI/liver bioregulation

Evidence level

Preclinical Evidence

Typical cycle

16 weeks

Longevity research motifLongevity

Ovagen in 30 seconds

Atlas Fast Read

What it is

Glu-Asp-Leu (EDL) ultrashort peptide bioregulator

Why people care

Peptide bioregulator research related to gastrointestinal and hepatic tissue function.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Ovagen is scientifically interesting for GI/liver bioregulation, cellular aging markers, but the current case is driven mainly by cell and animal data.

Overview

What is Ovagen?

Ovagen is glu-Asp-Leu (EDL) ultrashort peptide bioregulator. Peptide bioregulator research related to gastrointestinal and hepatic tissue function.

Ovagen belongs to the Khavinson ultrashort-peptide program. Its published evidence is largely in vitro and preclinical, with claims centered on tissue-specific gene regulation.

Mechanism

How it works

Ultrashort peptide proposed to enter cells and influence gene expression. In vitro EDL studies report changes in proliferation and aging-related markers such as p16, p21, p53, and SIRT6.

Research areas

GI/liver bioregulationcellular aging markersgene regulationtissue protection

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No modern, independently replicated controlled human trials establish Ovagen for liver, gastrointestinal, or longevity outcomes. Evidence is largely preclinical and derived from the broader short-peptide-bioregulator program.

Preclinical evidence

Cell models report tissue-specific effects on proliferation and age-related proteins, including p16/p21/p53 and sirtuin-related markers. Independent replication and in vivo translational evidence remain limited.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

community sources experimental reference: 10–150 mcg/day with slow titration. No controlled human dose is established.

Frequency

Once daily.

Timing

No established timing requirement.

Route

Subcutaneous in the community educational protocol.

Cycle length

16 weeks

Reconstitution

Community reference: 2 mL bacteriostatic water per 20 mg vial = 10 mg/mL; the very small proposed injection volumes create practical measurement concerns.

Storage

Community reference: lyophilized at -20 °C or colder; reconstituted 2–8 °C only briefly or aliquoted/frozen, avoiding repeated freeze-thaw.

Monitoring

No validated monitoring. If studied for GI/liver biology, CMP/liver enzymes and condition-specific outcomes are more relevant than generic longevity panels.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Human safety data are insufficient. Potential adverse effects include injection-site reactions, headache, fatigue, dizziness, nausea and unknown long-term effects on gene regulation, growth, metabolism or immune function.

Contraindications

No validated human contraindication profile exists. Avoid use outside research oversight in pregnancy/breastfeeding, active malignancy, significant organ disease or known hypersensitivity.

Interactions

Formal drug-interaction studies are absent or very limited. Interactions with anticancer, endocrine, metabolic and immunomodulatory therapies are unknown.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Ovagen is scientifically interesting for GI/liver bioregulation, cellular aging markers, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Longevity

Longevity

Cortagen

Peptide bioregulator research focused on neuroregeneration, brain aging, and cognitive function.

Read guide

Longevity

Epitalon

Pineal-derived tetrapeptide research exploring telomerase activity, circadian biology, and healthy aging.

Read guide

Longevity

FOXO4-DRI

Experimental senolytic peptide research investigating selective removal of senescent cells.

Read guide